News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
515,675 Results
Type
Article (40418)
Company Profile (122)
Press Release (475127)
Multimedia
Podcasts (113)
Webinars (15)
Section
Business (150729)
Career Advice (1776)
Deals (22475)
Drug Delivery (83)
Drug Development (60437)
Employer Resources (113)
FDA (11243)
Job Trends (10760)
News (247755)
Policy (21837)
Tag
Academia (2510)
Academic (2)
Accelerated approval (18)
Adcomms (21)
Allergies (94)
Alliances (42162)
ALS (148)
Alzheimer's disease (1614)
Antibody-drug conjugate (ADC) (206)
Approvals (11454)
Artificial intelligence (460)
Autoimmune disease (96)
Automation (27)
Bankruptcy (188)
Best Places to Work (8862)
BIOSECURE Act (18)
Biosimilars (118)
Biotechnology (93)
Bladder cancer (119)
Brain cancer (62)
Breast cancer (507)
Cancer (3743)
Cardiovascular disease (285)
Career advice (1525)
Career pathing (31)
CAR-T (197)
CDC (27)
Cell therapy (559)
Cervical cancer (27)
Clinical research (50847)
Collaboration (1389)
Company closure (3)
Compensation (412)
Complete response letters (31)
COVID-19 (2109)
CRISPR (79)
C-suite (544)
Cystic fibrosis (104)
Data (4887)
Decentralized trials (2)
Denatured (39)
Depression (102)
Diabetes (366)
Diagnostics (4743)
Digital health (31)
Diversity (7)
Diversity, equity & inclusion (31)
Drug discovery (231)
Drug pricing (109)
Drug shortages (21)
Duchenne muscular dystrophy (158)
Earnings (64158)
Editorial (46)
Employer branding (14)
Employer resources (100)
Events (78238)
Executive appointments (715)
FDA (13491)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (4)
Frontotemporal dementia (20)
Funding (1131)
Gene editing (152)
Generative AI (45)
Gene therapy (471)
GLP-1 (718)
Government (3184)
Grass and pollen (6)
Guidances (335)
Healthcare (14089)
HIV (42)
Huntington's disease (36)
IgA nephropathy (54)
Immunology and inflammation (165)
Immuno-oncology (28)
Indications (68)
Infectious disease (2269)
Inflammatory bowel disease (151)
Inflation Reduction Act (11)
Influenza (64)
Intellectual property (178)
Interviews (328)
IPO (10929)
IRA (38)
Job creations (2257)
Job search strategy (1262)
Kidney cancer (11)
Labor market (55)
Layoffs (322)
Leadership (30)
Legal (5254)
Liver cancer (61)
Longevity (11)
Lung cancer (511)
Lymphoma (300)
Machine learning (33)
Management (40)
Manufacturing (511)
MASH (124)
Medical device (8826)
Medtech (8850)
Mergers & acquisitions (12315)
Metabolic disorders (891)
Multiple sclerosis (130)
NASH (11)
Neurodegenerative disease (274)
Neuropsychiatric disorders (56)
Neuroscience (2625)
NextGen: Class of 2025 (4802)
Non-profit (3869)
Now hiring (23)
Obesity (384)
Opinion (238)
Ovarian cancer (121)
Pain (150)
Pancreatic cancer (158)
Parkinson's disease (247)
Partnered (29)
Patents (334)
Patient recruitment (307)
Peanut (36)
People (41451)
Pharmaceutical (21)
Pharmacy benefit managers (15)
Phase I (16211)
Phase II (22087)
Phase III (16803)
Pipeline (3473)
Policy (199)
Postmarket research (2076)
Preclinical (7363)
Press Release (60)
Prostate cancer (205)
Psychedelics (41)
Radiopharmaceuticals (210)
Rare diseases (587)
Real estate (3789)
Recruiting (47)
Regulatory (16383)
Reports (31)
Research institute (2396)
Resumes & cover letters (248)
Rett syndrome (20)
RNA editing (12)
RSV (47)
Schizophrenia (119)
Series A (195)
Series B (120)
Service/supplier (5)
Sickle cell disease (74)
Special edition (16)
Spinal muscular atrophy (131)
Sponsored (34)
Startups (2600)
State (1)
Stomach cancer (10)
Supply chain (65)
Tariffs (43)
The Weekly (73)
Vaccines (720)
Venture capital (53)
Weight loss (238)
Women's health (52)
Worklife (15)
Date
Today (9)
Last 7 days (165)
Last 30 days (1601)
Last 365 days (23880)
2025 (23816)
2024 (26837)
2023 (30083)
2022 (38501)
2021 (40916)
2020 (39270)
2019 (34527)
2018 (25749)
2017 (24059)
2016 (23602)
2015 (27163)
2014 (22248)
2013 (19483)
2012 (19709)
2011 (19434)
2010 (18164)
Location
Africa (711)
Alabama (75)
Alaska (6)
Arizona (157)
Arkansas (10)
Asia (30744)
Australia (5456)
California (7838)
Canada (2365)
China (829)
Colorado (337)
Connecticut (396)
Delaware (287)
Europe (70892)
Florida (1228)
Georgia (254)
Idaho (40)
Illinois (574)
India (49)
Indiana (410)
Iowa (15)
Japan (349)
Kansas (91)
Kentucky (35)
Louisiana (13)
Maine (39)
Maryland (1031)
Massachusetts (5846)
Michigan (217)
Minnesota (397)
Mississippi (3)
Missouri (102)
Montana (22)
Nebraska (14)
Nevada (82)
New Hampshire (44)
New Jersey (2359)
New Mexico (25)
New York (2239)
North Carolina (1028)
North Dakota (7)
Northern California (3814)
Ohio (208)
Oklahoma (17)
Oregon (24)
Pennsylvania (1596)
Puerto Rico (7)
Rhode Island (29)
South America (958)
South Carolina (31)
Southern California (3061)
Tennessee (135)
Texas (1251)
United States (28758)
Utah (234)
Vermont (1)
Virginia (174)
Washington D.C. (64)
Washington State (660)
West Virginia (4)
Wisconsin (68)
Wyoming (2)
515,675 Results for "brain and behavior discovery institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
WVU Rockefeller Neuroscience Institute and Cognito Therapeutics Launch Brain Health Collaboratory to Accelerate Neurotherapies with AI-powered Research
November 14, 2025
·
4 min read
Press Releases
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
November 6, 2025
·
5 min read
Press Releases
Researchers Highlight Genetic Factors in Pediatric Brain and Spinal Cord Tumors
November 24, 2025
·
6 min read
Press Releases
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
June 11, 2025
·
6 min read
Press Releases
BTT Medical Institute Announces Unprecedented Case of Total Reversal of ALS through Re-engineering of the Nobel Prize-Winning Fever Therapy into a Brain-Guided, Artificial Intelligence-Controlled ThermoFebrile Treatment
December 4, 2025
·
10 min read
Neurodegenerative disease
VectorY Bets up to $1.2B+ That Shape’s Brain-Penetrant Capsids Are a Fit
VectorY Therapeutics will evaluate the use of SHP-DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental Huntington’s and Alzheimer’s disease treatments.
September 18, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration
● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.
December 4, 2025
·
1 min read
Press Releases
Brain Canada invests in the next generation of brain researchers with new Future Leaders grants
October 1, 2025
·
4 min read
Press Releases
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
October 21, 2025
·
5 min read
Press Releases
Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
October 29, 2025
·
10 min read
1 of 51,568
Next
